Further, our results showed that Niv+Ipi has, regardless of the PD-L1 expression level, a better efficacy profile (PFS or OS) than Pem or Niv, which have already been approved as therapeutic options for PD-L1-positive advanced NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.